Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, The Netherlands.
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; Institute for Cardiovascular Research (ICaR), VU University Medical Center, Amsterdam, The Netherlands.
Gastroenterology. 2017 May;152(7):1671-1678. doi: 10.1053/j.gastro.2016.12.048. Epub 2017 Feb 10.
The potential role of intestinal microbiota in the etiology of various human diseases has attracted massive attention in the last decade. As such, the intestinal microbiota has been advanced as an important contributor in the development of obesity and obesity-related metabolic dysfunctions, amongst others. Experiments in animal models have produced evidence for a causal role of intestinal microbiota in the etiology of obesity and insulin resistance. However, with a few exceptions, such causal relation is lacking for humans and most publications merely report associations between intestinal microbial composition and metabolic disorders such as obesity and type 2 diabetes. Thus, the reciprocal relationship between the bacteria and these metabolic disorders remains a matter of debate. The main objective of this review is to critically assess the driving role of intestinal microbe composition in the etiology, prevention, and treatment of obesity and obesity-related metabolic dysfunction, including type 2 diabetes.
在过去的十年中,肠道微生物群在各种人类疾病的发病机制中的潜在作用引起了广泛关注。因此,肠道微生物群被认为是肥胖和肥胖相关代谢功能障碍等疾病发展的重要因素之一。动物模型实验为肠道微生物群在肥胖和胰岛素抵抗发病机制中的因果作用提供了证据。然而,除了少数例外情况,人类中缺乏这种因果关系,并且大多数出版物仅报告肠道微生物组成与肥胖和 2 型糖尿病等代谢紊乱之间的关联。因此,细菌与这些代谢紊乱之间的相互关系仍然存在争议。本综述的主要目的是批判性地评估肠道微生物组成在肥胖和肥胖相关代谢功能障碍(包括 2 型糖尿病)的发病机制、预防和治疗中的驱动作用。